Basilea Pharmaceutica AG (BPMUF)
77.40
0.00 (0.00%)
USD |
OTCM |
Sep 24, 16:00
Basilea Pharmaceutica Research and Development Expense (Annual) : 127.51M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 127.51M |
| December 31, 2024 | 87.60M |
| December 31, 2023 | 86.63M |
| December 31, 2022 | 77.28M |
| December 31, 2021 | 101.89M |
| December 31, 2020 | 103.78M |
| December 31, 2019 | 103.30M |
| December 31, 2018 | 107.23M |
| December 31, 2017 | 54.35M |
| Date | Value |
|---|---|
| December 31, 2016 | 49.18M |
| December 31, 2015 | 62.39M |
| December 31, 2014 | 59.40M |
| December 31, 2013 | 57.55M |
| December 31, 2012 | 62.78M |
| December 31, 2011 | 78.96M |
| December 31, 2010 | 53.73M |
| December 31, 2009 | 71.11M |
| December 31, 2008 | 89.96M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Santhera Pharmaceuticals Holding AG | 26.75M |
| BeOne Medicines Ltd. | 2.079B |
| AC Immune SA | 67.96M |
| CRISPR Therapeutics AG | 265.33M |
| Idorsia Ltd. | 121.54M |